Findings are from an exploratory subgroup analysis of the KEYNOTE-826 

Updated results from the KEYNOTE-756 trial show benefits of the chemoimmunotherapy across subgroups of patients with ER+/HER2− breast cancer

The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study

Despite being active in this disease setting, the antibody-drug conjugate was associated to high rates of neutropenic complications

Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies 

Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate

Promising new data are presented for nivolumab plus ipilimumab and the single tremelimumab regular interval durvalumab regimen in Asian patients and those with impaired liver function

Early results from a phase III trial support 30-minutes infusions of immunotherapy with some advantages for patients

Updated data from two studies report significant improvements in recurrence-free survival and distant-metastasis free survival with pembrolizumab or nivolumab 

Efficacy and safety of telisotuzumab adizutecan was investigated in patients with EGFR wild type non-squamous disease